

Title (en)
ANTITUMOR AGENT AND EVALUATION METHOD THEREOF

Title (de)
ANTITUMORMITTEL UND VERFAHREN ZU DESSEN BEURTEILUNG

Title (fr)
AGENT ANTITUMORAL ET SA MÉTHODE D'ÉVALUATION

Publication
EP 3815711 A4 20220810 (EN)

Application
EP 19826598 A 20190628

Priority

- JP 2018124894 A 20180629
- JP 2019025819 W 20190628

Abstract (en)
[origin: EP3815711A1] Provided is a novel cancer treatment method that exhibits a significantly excellent antitumor effect and causes less adverse reactions. The present invention provides an antitumor agent wherein a peptide having 4 linked epitopes and an immune checkpoint modulator are administered in combination. An antitumor effect in humans can be evaluated by providing a cell coexpressing an epitope peptide of a human tumor antigen derived from SART2 and human HLA-A24.

IPC 8 full level
A61K 39/00 (2006.01); **A61K 38/16** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/74** (2006.01); **C07K 19/00** (2006.01); **C12N 9/90** (2006.01)

CPC (source: EP KR US)
A61K 38/16 (2013.01 - EP KR); **A61K 39/0011** (2013.01 - EP KR); **A61K 39/001102** (2018.08 - EP KR US); **A61K 39/00119** (2018.08 - EP KR); **A61K 39/395** (2013.01 - EP KR); **A61K 39/3955** (2013.01 - US); **A61K 45/06** (2013.01 - KR); **A61K 47/65** (2017.08 - US); **A61P 35/00** (2018.01 - EP KR US); **C07K 14/4748** (2013.01 - EP); **C07K 14/70539** (2013.01 - EP); **C07K 16/2818** (2013.01 - EP); **C07K 16/2827** (2013.01 - EP); **C12N 9/90** (2013.01 - EP); **C12Y 501/03019** (2013.01 - EP); **G01N 33/5011** (2013.01 - KR); **A61K 38/00** (2013.01 - EP); **A61K 2039/505** (2013.01 - US); **A61K 2039/5156** (2013.01 - EP KR); **A61K 2039/545** (2013.01 - US); **A61K 2039/627** (2013.01 - US); **A61K 2039/645** (2013.01 - EP); **A61K 2039/70** (2013.01 - US); **A61K 2039/876** (2018.08 - EP); **A61K 2300/00** (2013.01 - KR); **C07K 2317/76** (2013.01 - EP)

C-Set (source: EP)
1. **A61K 39/395 + A61K 2300/00**
2. **A61K 38/16 + A61K 2300/00**

Citation (search report)

- [XD] WO 2015060235 A1 20150430 - TAIHO PHARMACEUTICAL CO LTD [JP]
- [Y] MASATOSHI HIRAYAMA ET AL: "The present status and future prospects of peptide-based cancer vaccines", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 7, 28 May 2016 (2016-05-28), GB, pages 319 - 328, XP055515960, ISSN: 0953-8178, DOI: 10.1093/intimm/dxw027
- [Y] SAKAMOTO SHINJIRO ET AL: "Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 65, no. 10, 22 August 2016 (2016-08-22), pages 1223 - 1231, XP036063239, ISSN: 0340-7004, [retrieved on 20160822], DOI: 10.1007/S00262-016-1887-5
- [T] TANAKA YUKI ET AL: "TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice", SCIENTIFIC REPORTS, vol. 10, no. 1, 14 October 2020 (2020-10-14), XP055896574, DOI: 10.1038/s41598-020-74187-6
- See also references of WO 2020004622A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
EP 3815711 A1 20210505; **EP 3815711 A4 20220810**; AU 2019293772 A1 20210128; AU 2019293772 B2 20240404; CN 112368016 A 20210212; JP 2020150950 A 20200924; JP 6716801 B2 20200701; JP WO2020004622 A1 20200716; KR 20210024601 A 20210305; KR 20240099456 A 20240628; MA 53026 A 20210505; TW 202019463 A 20200601; TW 202333769 A 20230901; TW I805792 B 20230621; US 2021236613 A1 20210805; WO 2020004622 A1 20200102

DOCDB simple family (application)
EP 19826598 A 20190628; AU 2019293772 A 20190628; CN 201980043981 A 20190628; JP 2019025819 W 20190628; JP 2020101090 A 20200610; JP 2020510633 A 20190628; KR 20217002430 A 20190628; KR 20247019245 A 20190628; MA 53026 A 20190628; TW 108122834 A 20190628; TW 112118616 A 20190628; US 201917255672 A 20190628